
NYSEHealthcareMedical - Devices
أحدث البيانات المتاحة
366.16 US$
+5.76 US$ · +1.60%
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
الإغلاق السابق
366.16 US$
+5.76 US$ · +1.60%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
نطاق اليوم
السعر الحالي 366.16 US$
نطاق 52 أسبوعًا
السعر الحالي 366.16 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
64
أقل من القيمة
المشاعر
66
صعودي
المخاطر
36
مخاطر متوسطة
الزخم
42
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
نطاق اليوم
السعر الحالي 366.16 US$
نطاق 52 أسبوعًا
السعر الحالي 366.16 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 2.58 مليار USD | 2.57 مليار USD | 2.67 مليار USD | 2.8 مليار USD | 2.92 مليار USD |
| تكلفة البضاعة المباعة | 1.24 مليار USD | 1.19 مليار USD | 1.24 مليار USD | 1.23 مليار USD | 1.28 مليار USD |
| الربح الإجمالي | 1.34 مليار USD | 1.38 مليار USD | 1.43 مليار USD | 1.57 مليار USD | 1.64 مليار USD |
| البحث والتطوير | 256.9 مليون USD | 295.9 مليون USD | 247.43 مليون USD | 256.89 مليون USD | 260.64 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 819.9 مليون USD | 814 مليون USD | 841.7 مليون USD | 827.83 مليون USD | 877.12 مليون USD |
| نفقات التشغيل | 1.08 مليار USD | 1.11 مليار USD | 1.09 مليار USD | 1.08 مليار USD | 1.14 مليار USD |
| دخل الفوائد | 95.5 مليون USD | 82 مليون USD | 100.9 مليون USD | 58 مليون USD | 18.9 مليون USD |
| مصاريف الفوائد | 49 مليون USD | 48.9 مليون USD | 49.44 مليون USD | 38.11 مليون USD | 1.55 مليون USD |
| الاستهلاك والإطفاء | 165.4 مليون USD | 151.6 مليون USD | 145.9 مليون USD | 137.3 مليون USD | 137.6 مليون USD |
| الدخل التشغيلي | 270.5 مليون USD | 269 مليون USD | 337.8 مليون USD | 482.62 مليون USD | 500.34 مليون USD |
| صافي الدخل | 759.9 مليون USD | −1.84 مليار USD | −637.32 مليون USD | −3.63 مليار USD | 4.25 مليار USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
350 US$
انخفاض محتمل بنسبة 4.41%| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 8 مارس 2002 | 2:1 | — | — |
تقسيم الأسهم | 3 يونيو 1996 | 3:2 | — | — |
تقسيم الأسهم | 11 يونيو 1986 | 3:2 | — | — |
تقسيم الأسهم | 1 أغسطس 1985 | 3:2 | — | — |
تقسيم الأسهم | 18 مارس 1980 | 2:1 | — | — |
ساري 8 مارس 2002
2:1
ساري 3 يونيو 1996
3:2
ساري 11 يونيو 1986
3:2
ساري 1 أغسطس 1985
3:2
ساري 18 مارس 1980
2:1
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI226.26 مليون0.01%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Morningstar Small-Cap ETFVB163.87 مليون0.09%185.3 مليار USD0.03%289.48 US$+0.64%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV147.95 مليون0.55%26.81 مليار USD0.33%37.95 US$-0.39%
Vanguard Morningstar Small-Cap Value ETFVBR104.07 مليون0.15%68.2 مليار USD0.05%234.43 US$+0.22%
Vanguard Extended Market ETFVXF80.86 مليون0.08%95.4 مليار USD0.05%235 US$+0.80%
Dimensional - US Small Cap ETFDFAS52.91 مليون0.16%33.87 مليار USD0.31%78.35 US$+0.32%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY48.76 مليون0.19%25.82 مليار USD0.23%669.87 US$+0.54%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD35.12 مليون0.19%18.27 مليار USD0.03%64.33 US$+0.56%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMDالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.